Charles River Laboratories (CRL) was Reiterated by Barclays to “Underweight” according to the research note released today. The brokerage firm has raised the Price Target to $ 65 from a previous price target of $60 . Barclays advised their investors in a research report released on May 20, 2016.
Many Wall Street Analysts have commented on Charles River Laboratories. Gabelli & Co Initiated Charles River Laboratories on Apr 26, 2016 to “Buy”, Price Target of the shares are set at $96.
On the company’s financial health, Charles River Laboratories reported $0.98 EPS for the quarter, beating the analyst consensus estimate by $ 0.08 according to the earnings call on May 4, 2016. Analyst had a consensus of $0.90. The company had revenue of $354.90 million for the quarter, compared to analysts expectations of $354.81 million. The company’s revenue was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.79 EPS.
Charles River Laboratories closed down -0.23 points or -0.27% at $83.69 with 2,22,736 shares getting traded on Thursday. Post opening the session at $83.62, the shares hit an intraday low of $82.81 and an intraday high of $84.35 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
In a different news, on May 16, 2016, Richard F Wallman (director) sold 1,970 shares at $82.34 per share price. According to the SEC, on May 10, 2016, George Massaro (director) sold 985 shares at $82.04 per share price. On Apr 8, 2016, Davide Molho (Corporate Executive VP) sold 30,667 shares at $80.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Charles River Laboratories International Inc. is a full service early stage contract research company. The Company offers research models for the research and development of new drugs devices and therapies. It develops a portfolio of discovery and safety assessment services both Good Laboratory Practice (GLP) and non-GLP that support the clients from target identification through preclinical development. The Company operates through three segments: Research Models and Services (RMS) which supplies research models to the drug development industry; Discovery and Safety Assessment (DSA) which provides services that enables the clients to outsource their drug discovery research critical regulatory-required safety assessment testing and related drug discovery and development activities and Manufacturing Support (Manufacturing) which is involved in the production and release of products manufactured by the clients.